Evoke pharma inc (EVOK)
Balance Sheet / Yearly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Dec'13Sep'13Dec'12
Assets
Current Assets:
Cash and cash equivalents

4,133

5,663

6,504

7,440

4,028

5,319

6,567

6,531

5,405

7,679

10,412

12,556

14,654

9,007

10,379

4,129

6,099

8,691

10,738

9,883

11,692

14,155

12,176

16,045

21,835

24,196

23,738

116

Prepaid expenses

387

581

775

109

219

329

438

83

167

251

334

587

171

267

425

499

764

833

935

716

858

931

1,131

888

176

234

-

-

Other current assets

11

-

11

11

11

-

-

11

11

-

-

-

-

7

7

7

7

-

-

7

23

137

-

-

-

-

-

-

Total current assets

4,532

6,245

7,291

7,561

4,259

5,648

7,006

6,626

5,584

7,930

10,747

13,144

14,826

9,282

10,813

4,636

6,872

9,524

11,674

10,607

12,574

15,225

13,308

16,934

22,011

24,430

23,738

116

Operating lease right-of-use asset

105

138

35

69

103

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Other assets

-

11

-

-

-

11

11

-

-

11

11

11

11

11

-

-

-

7

7

-

47

7

82

88

555

555

-

-

Total assets

4,637

6,395

7,327

7,631

4,362

5,659

7,018

6,626

5,584

7,941

10,759

13,155

14,838

9,294

10,813

4,636

6,872

9,532

11,682

10,607

12,621

15,233

13,390

17,023

22,567

24,986

23,738

116

Liabilities and stockholders' equity
Current Liabilities:
Accounts payable and accrued expenses

925

1,033

1,154

407

491

476

625

441

545

1,048

1,720

1,121

549

478

498

1,264

1,243

927

1,337

1,372

1,353

1,011

1,049

1,299

1,115

284

1,176

96

Accrued compensation

685

843

964

807

692

1,158

984

824

649

1,025

927

757

586

933

513

499

482

760

665

563

424

697

636

537

385

557

390

417

Operating lease liability

105

138

35

69

103

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Other current liabilities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

3

5

9

12

-

-

-

-

-

-

Current portion of long-term debt

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

4,399

708

146

-

1,251

712

126

-

-

1,442

1,442

1,069

-

Total current liabilities

1,716

2,015

2,154

1,285

1,287

1,634

1,610

1,265

1,195

2,074

2,648

1,879

1,135

1,411

1,011

6,163

2,434

1,834

2,006

3,194

2,499

1,847

1,685

1,837

2,943

2,284

2,637

570

Warrant liability

-

-

-

-

-

-

-

-

-

3,701

6,050

4,506

5,768

4,095

5,098

-

-

-

-

-

-

-

-

-

-

-

-

56

Other long-term liabilities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

6

-

-

Deferred rent expense

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

14

16

15

-

-

0

Long-term debt, net of current portion

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

3,680

4,233

4,368

3,101

3,688

4,196

-

-

1,156

1,511

1,878

979

Total liabilities

-

-

-

-

-

-

1,610

1,265

1,195

5,776

8,699

6,385

6,904

5,506

6,110

6,163

6,115

6,067

6,374

6,296

6,187

6,044

1,700

1,853

4,116

3,803

4,515

1,550

Commitments and contingencies

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

0

-

-

-

0

-

-

-

0

0

0

Stockholders' equity:
Preferred stock, $0.0001 par value; authorized shares — 5,000,000 at December 31, 2019 and 2018; issued and outstanding shares — 0 at December 31, 2019 and 2018

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

0

-

-

-

0

-

-

-

0

0

0

Common stock, $0.0001 par value; authorized shares - 50,000,000; issued and outstanding shares - 24,456,914 and 24,431,914 at March 31, 2020 and December 31, 2019, respectively

2

2

2

2

1

1

1

1

1

1

1

1

1

1

1

0

0

0

0

0

0

0

0

0

0

0

0

0

Additional paid-in capital

90,439

90,108

89,482

89,027

83,643

82,628

82,250

80,683

77,409

73,202

72,788

72,255

71,793

62,595

61,983

52,728

52,042

51,524

50,743

47,012

45,892

45,127

-

-

-

43,874

-

-

Additional paid-in capital

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

44,709

44,362

44,097

-

40,296

195

Accumulated deficit

-87,520

-85,730

-84,312

-82,684

-80,570

-78,604

-76,844

-75,324

-73,021

-71,038

-70,730

-65,487

-63,861

-58,809

-57,281

-54,256

-51,286

-48,060

-45,436

-42,701

-39,459

-35,939

-33,019

-29,193

-

-22,691

-

-

Deficit accumulated during the development stage

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

25,646

-

21,074

19,855

Total stockholders' equity

2,921

4,380

5,173

6,346

3,075

4,025

5,407

5,360

4,389

2,165

2,059

6,769

7,933

3,787

4,703

-1,526

757

3,464

5,307

4,311

6,433

9,188

11,690

15,169

18,451

21,183

19,222

-19,659

Total liabilities and stockholders' equity

4,637

6,395

7,327

7,631

4,362

5,659

7,018

6,626

5,584

7,941

10,759

13,155

14,838

9,294

10,813

4,636

6,872

9,532

11,682

10,607

12,621

15,233

13,390

17,023

22,567

24,986

23,738

116